Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 | Kisspeptin-10 | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury. | Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation. |
| Timing | Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing. | Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity. |
| Cycle Duration | Typical cycles range from 4-12 weeks depending on the injury being addressed. | Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.
Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.
Typical cycles range from 4-12 weeks depending on the injury being addressed.
Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.
Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.
Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.
Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →